Advertisement

Anjali Mishra, PhD, and Nitin Chakravarti, PhD, Join Sidney Kimmel Cancer Center at Jefferson Health


Advertisement
Get Permission

The Sidney Kimmel Cancer Center–Jefferson Health (SKCC) recently welcomed Anjali Mishra, PhD, and Nitin Chakravarti, PhD, to its team of researchers focused on hematologic cancers. Both Drs. Mishra and Chakravarti are Assistant Professors in the Department of Medical Oncology.

Dr. Mishra is a cancer biologist studying the pathogenetic mechanisms in cytokine-driven leukemias and lymphomas. Her research focuses on the effects of chronic inflammation in blood cancers and on developing ­novel therapies for T-cell lymphomas and leukemias using an interleukin-15 (IL-15) mouse model that she characterized. Dr. Mishra’s current research goals include defining the molecular mechanisms underlying IL-15–mediated oncogenesis and identifying novel targets in blood cancers driven by IL-15 overexpression.

Anjali Mishra, PhD

Anjali Mishra, PhD

Dr. Mishra is an associate editor of the journal Frontiers in Oncology and a reviewer for Clinical Cancer Research, PLOS One, Blood, and Haematologica. She is an active member of the American Society of Hematology (ASH), European Hematology Association (EHA), Society for Investigative Dermatology (SID), Cutaneous Lymphoma Foundation (CLF), and American Association for Cancer Research (AACR).

Dr. Mishra received her undergraduate degree from the University of Delhi in New Delhi, India, a doctoral degree from Hannover Medical School in Hannover, Germany, and completed postdoctoral training at The Ohio State University.

Dr. Chakravarti’s previous research has identified clinical associations of retinoid signaling pathways and cancer progression; novel strategies to overcome resistance to targeted and immune therapies; and new predictors and therapeutic approaches for cancer. Dr. Chakravarti’s laboratory currently studies the regulation and functional role of retinoid signaling pathways in carcinogenesis. His research goals include studying immune checkpoint and cell-based immunotherapeutic approaches to treatment of blood cancers.

Dr. Chakravarti joins SKCC from the Center for Childhood Cancer and Blood Diseases at Nationwide Children’s Hospital (NCH) in Columbus, Ohio, where he was a senior research scientist. He received his master’s degree from the Indian Institute of Technology–Roorkee and a doctorate from the All India Institute of Medical Sciences (AIIMS) in New Delhi, India. Dr. Chakravarti completed his postdoctoral training in bioimmunotherapy and the Department of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center in Houston, where he later continued as a junior faculty, prior to joining NCH. 


Advertisement

Advertisement



Advertisement